Clinical Trial Update: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1 [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the safety, tolerability and efficacy of Simeprevir (TMC435) with pegylated interferon alfa-2a and ribavirin in chronic hepatitis C gen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)
• Simeprevir (simeprevir)

Snippet

Sponsor: Janssen R&D Ireland | Conditions: Hepatitis C Virus Genotype-1 | Phase 3 | Status: COMPLETED | Results posted: 2014-10-29